| 14.28 1.74 (13.88%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.76 |
1-year : | 20.74 |
| Resists | First : | 15.21 |
Second : | 17.76 |
| Pivot price | 12.17 |
|||
| Supports | First : | 12.37 |
Second : | 10.61 |
| MAs | MA(5) : | 12.22 |
MA(20) : | 12.32 |
| MA(100) : | 9.45 |
MA(250) : | 8.7 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.2 |
D(3) : | 39.2 |
| RSI | RSI(14): 64 |
|||
| 52-week | High : | 17.39 | Low : | 4.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KZIA ] has closed Bollinger Bands are 13% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.42 - 14.46 | 14.46 - 14.51 |
| Low: | 12.48 - 12.53 | 12.53 - 12.58 |
| Close: | 14.19 - 14.27 | 14.27 - 14.36 |
Kazia Therapeutics Limited is a biotechnology firm primarily dedicated to creating pharmaceutical treatments for cancer. Its leading therapeutic asset is Paxalisib, a distinctive small molecule that can penetrate the brain and works by inhibiting the PI3K/Akt/mTor pathway, showing promise as a potential remedy for glioblastoma. The company is also progressing with EVT801, an experimental medication being investigated for its efficacy against various cancer types. Incorporated in 1994, the entity operated under the name Novogen Limited until its rebranding to Kazia Therapeutics Limited in November 2017. The company's main operations are based in Sydney, Australia.
Thu, 11 Jun 2026
Lake Street Initiates Kazia Therapeutics(KZIA.US) With Buy Rating, Announces Target Price $32 - Moomoo
Thu, 11 Jun 2026
KZIA Initiated Coverage by Lake Street -- Price Target Set at $3 - GuruFocus
Thu, 11 Jun 2026
Lake Street Initiates Coverage on Kazia Therapeutics With Buy Rating, $32 Price Target - marketscreener.com
Thu, 11 Jun 2026
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bi - GuruFocus
Tue, 02 Jun 2026
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO - Stock Titan
Tue, 02 Jun 2026
Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 4.02e+009 (%) |
| Held by Institutions | 19.8 (%) |
| Shares Short | 186 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.784e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 641 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 1.9e+006 % |
| Gross Profit (p.s.) | 140.08 |
| Sales Per Share | -47.94 |
| EBITDA (p.s.) | 852018 |
| Qtrly Earnings Growth | -7.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 1 |
| Price to Book value | 0 |
| Price to Sales | -0.3 |
| Price to Cash Flow | 10.75 |
| Dividend | 0 |
| Forward Dividend | 362700 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|